IGHE and medium chain acyl-CoA dehydrogenase deficiency: Omalizumab, a humanized anti-IgE murine monoclonal antibody, binds to the domain of the Fc region of IgE preventing mast cell activation and has been deemed safe and effective in case reports of mast cell activation disease (MCAD; Molderings et al., 2016).